Adalimumab · subcutaneous injection
Misc., Injections & Implants
Approved uses
Non-infectious intermediate, posterior and panuveitis, adults
80 mg subcutaneously once, then 40 mg every other week starting one week later
The reason an optometrist opens this card; the rest of its label is rheumatology
Non-infectious intermediate, posterior and panuveitis, children aged 2 and over
10 mg every other week at 10 to under 15 kg; 20 mg every other week at 15 to under 30 kg; 40 mg every other week at 30 kg and above
Contraindications
None.
Pen 80 mg/0.8 mL, 40 mg/0.8 mL, 40 mg/0.4 mL; prefilled syringe 80 mg/0.8 mL, 40 mg/0.8 mL, 40 mg/0.4 mL, 20 mg/0.2 mL, 10 mg/0.1 mL
Adalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement. Adalimumab does not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated concentrations of TNF are found in the synovial fluid of patients with RA, JIA, PsA, and AS and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Increased concentrations of TNF are also found in psoriasis plaques.
Warnings & Precautions
- Serious infections: Patients treated with HUMIRA are at increased risk for serious infections that may lead to hospitalization or death, including tuberculosis, bacterial sepsis, invasive fungal infections (such as histoplasmosis) and infections due to other opportunistic pathogens. Do not start HUMIRA during an active infection. Discontinue HUMIRA if a patient develops a serious infection or sepsis. This carries a boxed warning.
- Tuberculosis: Test patients for latent TB before HUMIRA use and during therapy, and start treatment for latent TB before starting HUMIRA. Monitor all patients for active TB during treatment, even if the initial latent TB test is negative. The boxed warning includes this testing.
- Invasive fungal infections: Patients may present with disseminated rather than localized disease, and antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk who develop severe systemic illness, especially those who reside or travel in regions where mycoses are endemic.
- Malignancy: Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including HUMIRA. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL) have been fatal. Most reported cases occurred in patients with Crohn's disease or ulcerative colitis, and most were in adolescent and young adult males. This is also a boxed warning.
- Malignancies: In controlled trials of some TNF blockers, including HUMIRA, more malignancies were observed in treated adults than in controls. Consider the risks and benefits before starting HUMIRA in patients with a known malignancy other than a successfully treated non-melanoma skin cancer (NMSC). Examine all patients for NMSC before and during treatment.
- Hypersensitivity reactions: Anaphylaxis and angioneurotic edema have been reported following HUMIRA administration. If an anaphylactic or other serious allergic reaction occurs, immediately discontinue HUMIRA and institute appropriate therapy.
- Hepatitis B virus reactivation: TNF blockers, including HUMIRA, may increase the risk of HBV reactivation in chronic carriers, and some cases have been fatal. Evaluate patients at risk for HBV infection before starting. Monitor carriers during therapy and for several months after it ends. If reactivation occurs, stop HUMIRA and begin anti-viral therapy.
- Demyelinating disease: TNF blockers, including HUMIRA, have been associated with rare cases of new onset or exacerbation of central nervous system demyelinating disease, including multiple sclerosis and optic neuritis, and peripheral demyelinating disease, including Guillain-Barré syndrome. Exercise caution in patients with preexisting or recent-onset demyelinating disorders, and consider discontinuation if any develop. Intermediate uveitis has a known association with central demyelinating disorders.
- Cytopenias: Pancytopenia, including aplastic anemia, has rarely been reported with TNF blocking agents, and cytopenias such as thrombocytopenia and leukopenia have been infrequently reported with HUMIRA. The causal relationship of these reports to HUMIRA remains unclear. Advise patients to seek immediate medical attention for signs of blood dyscrasias or infection (e.g., persistent fever, bruising, bleeding, pallor). Consider discontinuation in patients with confirmed significant hematologic abnormalities.
- Heart failure: Worsening and new onset congestive heart failure (CHF) have been reported with TNF blockers, and worsening CHF has been observed with HUMIRA. Exercise caution when using HUMIRA in patients who have heart failure and monitor them carefully.
- Autoimmunity: Treatment with HUMIRA may result in the formation of autoantibodies and, rarely, a lupus-like syndrome or autoimmune hepatitis. If symptoms and findings suggestive of either develop, discontinue treatment and evaluate the patient.
- Immunizations: Patients on HUMIRA may receive concurrent vaccinations, except for live vaccines. Pediatric patients should, if possible, be brought up to date with all immunizations before starting HUMIRA. The safety of live or live-attenuated vaccines in infants exposed to HUMIRA in utero is unknown, so consider risks and benefits before vaccinating them.
- Increased risk of infection: Concurrent use of anakinra and another TNF blocker was associated with more serious infections and neutropenia and no added benefit in patients with RA. Concurrent use of abatacept and TNF blockers was associated with more serious infections and no improved clinical benefit in RA. The combination of HUMIRA with anakinra or with abatacept is not recommended.
Common Side Effects
The most common adverse reactions (more than 10%) are infections (for example upper respiratory infection and sinusitis), injection site reactions, headache and rash. In placebo-controlled trials, 20% of subjects treated with HUMIRA developed injection site reactions, compared to 14% of subjects receiving placebo.
Pregnancy: Available studies do not reliably establish an association between adalimumab and major birth defects. Adalimumab is actively transferred across the placenta during the third trimester and may affect immune response in the in-utero exposed infant. Consider risks and benefits before giving live or live-attenuated vaccines to infants exposed to HUMIRA in utero.
Lactation: Limited data from case reports describe adalimumab in human milk at infant doses of 0.1% to 1% of the maternal serum concentration. Published data suggest that systemic exposure to a breastfed infant is expected to be low because adalimumab is a large molecule and is degraded in the gastrointestinal tract. However, the effects of local exposure in the gastrointestinal tract are unknown. There are no reports of adverse effects on the breastfed infant and no effects on milk production.
The safety and effectiveness of HUMIRA have not been established in pediatric patients with psoriatic arthritis, ankylosing spondylitis, or plaque psoriasis. Safety and effectiveness have been established for non-infectious intermediate, posterior and panuveitis in pediatric patients 2 years of age and older, and have not been established in pediatric patients with uveitis less than 2 years of age. Other established pediatric uses are polyarticular JIA (2 years and older), Crohn's disease (6 years and older), ulcerative colitis (5 years and older) and hidradenitis suppurativa (12 years and older). Post-marketing cases of lymphoma, including hepatosplenic T-cell lymphoma, and other malignancies, some fatal, have been reported among children, adolescents and young adults who received TNF blockers including HUMIRA.